The EPMA World Congress on Predictive, Preventive & Personalised Medicine (PPPM)

Organisers:
Olga Golubnitschaja
Vincenzo Costigliola

Specialised Sessions:
- Healthcare in overview across the globe
- Collaboration with global organisations
- Granting strategies in PPPM
- PPPM-related Education
- Primary Prevention, Body Culture, Sport Medicine
- PPPM in Reproductive Medicine
- PPPM early in life: Neonatology, Paediatrics
- PPPM in Diabetes care
- PPPM in Neurodegeneration
- PPPM in Cancer
- PPPM in Cardiovascular Pathologies
- Clustered PPPM-Centres, Validation and Standards
- Patients’ needs: Round-table with GPs and Organised Patients’ Groups
- Ethical, Legal and Social Issue
- Patients’ modelling in PPPM
- Role of Laboratory Medicine in PPPM
- PPPM-related Bio-Banking
- Drug-diagnostics co-development and commercialisation strategies
- Private-public partnerships

www.epmanet.eu
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Animal Models of N-Methyl-N-nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials. A. TSUBURA, Y.-C. LAI, H. MIKI, T. SASARI, N. UEHARA, T. YURI, K. YOSHIZAWA (Osaka, Japan)


Effects of Combined Insulin-like Growth Factor 1 and Macrophage Colony-stimulating Factor on the Skeletal Properties of Mice. S.A. LLOYD, S.J. SIMSKE, L.K. BOGREN, S.E. OLESIAK, T.A. BATEMAN, V.L. FERGUSON (Hershey, PA; Boulder, Fort Collins, CO; Chapel Hill, NC, USA)

Cell Death Detection after High-LET Irradiation in an Orthotopic Human Hepatocellular Carcinoma in Vivo. A. ALTMEYER, M. IGNAT, J.-M. DENIS, N. MESSADDEQ, J. GUEULETTE, D. MUTTER, P. BISCHOFF (Strasbourg; Illkirch Graffenstaden, France; Brussels, Belgium)

Serum Calcium-decreasing Factor, Caldecrin, Ameliorates Muscular Dystrophy in dy/dy Mice. M. TOMOMURA, T. FUJII, H. SAKAGAMI, A. TOMOMURA (Saitama; Tokushima, Japan)

Nitric Oxide Concentrations are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NIJS (Antwerpen, Brussel, Belgium)

Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (Loma Linda, CA, USA)

Colon Cancer Vaccines: An Update. E. MERIKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (London, UK; Haven, CT; Durham, NC, USA; Athens, Greece)

Novel Microminipig Model of Atherosclerosis by High Fat and High Cholesterol Diet, Established in Japan. N. MIYOSHI, M. HORIUCHI, Y. INOKUCHI, Y. MIYAMOTO, N. MIURA, S. TOKUNAGA, M. FUJIKI, Y. IZUMI, H. MIYAJIMA, R. NAGATA, K. MISUMI, T. TAREUCHI, A. TAMINOTO, N. YASUDA, H. KAWAGUCHI (Kagoshima, Osaka, Japan)

CD95 and TNFα-induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (Münster; Köln; Heidelberg, Germany)


Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEIROS, L. AMARAL (Odense; Copenhagen, Denmark; Lisbon, Portugal)


A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCCOLI, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (San Giovanni Rotondo; Florence, Italy)

Urine and Serum Analysis of Consumed Curcuminoids Using an IκB-luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C. HOUCHEN, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (Oklahoma City, OK, USA)

Chemoradiation-induced Changes in Serum CEA and Plasma TIMP-1 in Patients with Locally Advanced Rectal Cancer. B. ALDULAYMI, I.J. CHRISTENSEN, G. SØLÆTORMOS, P. JESS, S.E. NIELSEN, S. LAURBERG, N. BRÜNNER, H.J. NIELSEN (Hillerød; Copenhagen; Aarhus; Frederiksberg; Hvidovre, Denmark) ........................................................................................................................................ 4755

Prognostic Significance of Fluorescent In Situ Hybridisation in the Follow-up of Non-muscle-invasive Bladder Cancer. M. MAFFEZZINI, F. CAMPODONICO, G. CAPPONI, G. CANEPA, S. CASAZZA, R. BANDELLONI, S. TAMAGNO, M. PUNTONI (Genova, Italy) ........................................................................................................................................ 4761

Neoadjuvant Bevacizumab in a Granulosa Cell Tumor of the Ovary: A Case Report. N.I. BARRENA MEDEL, T.J. HERZOG, J.D. WRIGHT, S.N. LEWIN (New York, NY, USA; Santiago, Chile) ........................................................................................................................................ 4767


XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer. S. CEREDA, M. RENI, A. ROGNONE, M. GHIDINI, C. BELL, S. LONGONI, C. FUGAZZA, M. BRIOSCHI, R. NICOLETTI, G. BALZANO, P. PASSONI, E. VILLA (Milan, Italy) ........................................................................................................................................ 4785

* Reviews (pages 4477, 4673)
Caregiver Distress in the Early Phases of Cancer. R. PELLEGRINO, V. FORMICA, I. PORTARENA, S. MARIOTTI, I. GRENGA, G. DEL MONTE, M. ROSELLI (Rome, Italy) .......................................................... 4657

A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer. T. SHIMIZU, A. HIRANO, M. KAMIMURA, K. OGURA, N. KIM, O. WATANABE, J. KINOSHITA, K. KIMURA, K. OGAWA, M. FUJIBAYASHI (Tokyo, Japan) .......................................................... 4665

* Review: Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma. W.C.M. DEMPEKE, V. HEINEMANN (Riesa; Munich, Germany) .......................................................... 4673

Myxoid Liposarcoma with EWS–CHOP Type 1 Fusion Gene. K. SUZUKI, Y. MATSUI, K. ENDO, T. KUBO, T. HASEGAWA, T. KIMURA, O. OHTANI, N. YASUI (Toyama; Tokushima; Hokkaido, Japan) ............................. 4679

Ectomesenchymal Chondromyxoid Tumour of the Tongue. A Review of Histological and Immunohistochemical Features. F. ANIGERO (Monza, Italy) ................................................................................. 4685

Video-assisted Thoracoscopic Pericardiectomy for Malignant Pericardial Effusion. H. URAMOTO, T. HANAGIRI (Kitakyushu, Japan) ........................................................................................................ 4691

A Randomized Phase II Trial of Adjuvant Chemotherapy with Bi-weekly Carboplatin plus Paclitaxel versus Carboplatin plus Gemcitabine in Patients with Completely Resected Non-small Cell Lung Cancer. H. URAMOTO, R. NAKANISHI, A. NAGASHIMA, A. UCHIYAMA, M. INOUE, T. OSAKI, T. YOSHIMATSU, H. SAKATA, K. NAKANISHI, K. YASUMOTO (Kitakyushu; Joetsu; Fukuoka, Japan) .... 4695

Hormone Receptor Rate, MIB-1 Score and Serum Tumour Markers CEA and CA 15-3 Relationship in Elderly Women with pT1-2 Breast Cancer. F. LUMACHI, L. NORBERTO, F. MARINO, S.M.M. BASSO, B. MARZANO, G.B. CHIARA (Padova; Pordenone, Italy) ........................................................ 4701


A Pilot Study of Gemcitabine in Combination with Oxaliplatin and Vinorelbine in Patients with Metastatic Bladder Cancer. D. POUESSEL, H. HUGUET, F. IBORRA, X. REBILLARD, D. AYUSO, C. BECHT, S. CULINE (Montpellier; Sète, France) .............................................................. 4711

Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung. H. URAMOTO, S. YAMADA, T. HANAGIRI (Kitakyushu, Japan) .......................................................... 4717


c-Kit Expression and Mutations in Phyllodes Tumors of the Breast. P. BOSE, S. TERENCE DUNN, J. YANG, R. ALLEN, C. EL-KHOURY, A. TFAYLI (Oklahoma, OK, USA) .......................................................... 4731

Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels. A. SCIARRA, S. SALCICCIA, G. NESI, S. CATTARINO, A. ALFARONE, A. GENTILUCCI, V. GENTILE (Rome, Italy) .......................................................... 4737

Wound Complications after Bevacizumab Treatment in Patients Operated on for Ovarian Cancer. M. KOSKAS, E. CHEREAU, M. BALLESTER, F. SELLE, R. ROUZIER, E. DARAI (Paris, France) ........................................................................ 4743

LOXL4 as a Selective Molecular Marker in Primary and Metastatic Head/Neck Carcinoma. N. SCOLA, T. GÖRÖGH (Bochum; Kiel, Germany) ........................................................................................................ 4567

Analysis of the Cytotoxic Activity of Carboplatin and Gemcitabine Combination. S. WANG, H. ZHANG, L. CHENG, C. EVANS, C.-X. PAN (Sacramento; Mather, CA; Indianapolis, IN, USA; Changchun, China) ........................................................................................................................................ 4573

EGF-dependent Induction of BCL-xL and p21CIP1/WAF1 Is Highly Variable in HNSCC Cells – Implications for EGFR-targeted therapies. J. RÜDDEL, V.E. WENNEKES, W. MEISSNER, J.A. WERNER, R. MANDIC (Marburg, Germany) .................................................. 4579

Stilbenes as Multidrug Resistance Modulators and Apoptosis Inducers in Human Adenocarcinoma Cells. O. WESOLONSKA, J. WIŚNIEWSKI, A. BIELAWSKA-POHL, M. PAPROCKA, N. DUARTE, M.-J. U. FERREIRA, D. DUŠ, K. MICHALAK (Wrocław, Poland; Lisbon, Portugal) .................................................................................................................. 4587

Methylation of AKAP12α Promoter in Lung Cancer. U.H. JO, Y.M. WHANG, J.S. SUNG, Y.H. KIM (Seoul, South Korea) ............................................................................................................................... 4595

Influence of Clofarabine on Transcriptional Activity of PTEN, APC, RARB2, ZAP70 Genes in K562 Cells. K. MAJDA, A. KAUFMAN-SZYMCZYK, K. LUBECKA-PIETRUSZEWSKA, A. BEDNAREK, K. FABIANOWSKA-MAJEWSKA (Lodz, Poland) .................................................................................................................. 4601


In Vitro Cytotoxicity of Benzopyranone Derivatives with Basic Side Chain Against Human Lung Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO, C. WARYOBA, N. UGOCHUKWU (Tallahassee, FL, USA) .................................................................................................................................................. 4613

Additive Growth Inhibition after Combined Treatment of 2-Methoxyestradiol and Conventional Chemotherapeutic Agents in Human Pancreatic Cancer Cells. C. FOTOPOULOU, D. BAUMUNK, S.C. SCHMIDT, G. SCHUMACHER (Berlin, Germany) ............................................................................................................................. 4619

Inhibition of CK2α and PI3K/Akt Synergistically Induces Apoptosis of CD34+CD38− Leukaemia Cells while Sparing Haematopoietic Stem Cells. J.-W. CHEONG, Y. H. MIN, J.I. EOM, S.J. KIM, H.K. JEUNG, J.S. KIM (Seoul, South Korea) .......................................................................................................................... 4625

Clinical Studies

Expression of β-Catenin, MUC1 and c-Met in Diffuse-type Gastric Carcinomas: Correlations with Tumour Progression and Prognosis. M.F. RETTERSPITZ, S.P. MÖNIG, S. SCHRECKENBERG, P.M. SCHNEIDER, A.H. HÖLSCHER, H.P. DIENES, S.E. BALDUS (Cologne; Duesseldorf, Germany; Zuerich, Switzerland) .................................................................................................................................................. 4635

DNA Content and Methylation of p16, DAPK and RASSF1A Gene in Tumour and Distant, Normal Mucosal Tissue of Head and Neck Squamous Cell Carcinoma Patients. N. LAYTRAGOON-LEWIN, F. CHEN, J. CASTRO, G. ELMBERGER, L.E. RUTQVIST, F. LEWIN, I. TURESSON, J. LUNDGREN (Uppsala; Jönköping; Stockholm, Sweden) .......................................................................................................................... 4643


Contents continued on the preceding page
Intraductal Tubular Carcinoma of the Pancreas: Case Report with Review of Literature. M. HIOKI, T. NAKAGOHRI, T. IKUMOTO, N. GOTOHDA, S. TAKAHASHI, M. KONISHI, M. KOJIMA, T. KINOSHITA (Kanagawa; Kobe; Chiba, Japan) ................................................................. 4435

Sporadic TP53 Transition Mutations in Chronic Cholecystitis Are Possibly Linked to Gallbladder Carcinogenesis. N. YANAGISAWA, K. YAMASHITA, T. KUBA, I. OKAYASU (Kanagawa, Japan) .................................................. 4443

Specific Copy Number Alterations Associated with Docetaxel/Carboplatin Response in Ovarian Carcinomas. L. ÖSTERBERG, K. LEVAN, K. PARTHEEN, U. DELLE, B. OLSSON, K. SUNDFELDT, G. HORVATH (Gothenburg; Skövde, Sweden) ................................................................. 4451

Proteomic Differential Display Analysis Shows Up-regulation of 14-3-3 Sigma Protein in Human Scirrhous-Type Gastric Carcinoma Cells. Y. KURAMITSU, B. BARON, S. YOSHINO, X. ZHANG, T. TANAKA, M. YASHIRO, K. HIRAKAWA, M. OKA, K. NAKAMURA (Ube; Osaka, Japan) .................................................. 4459

Effect of Hyperbaric Oxygen on the Anticancer Effect of Artemisinin on Molt-4 Human Leukemia Cells. Y. OHGAMI, C.A. ELSTAD, E. CHUNG, D.Y. SHIRACHI, R.M. QUOCK, H.C. LAI (Pullman; Seattle, WA; Chico, CA, USA) .................................................................................................................. 4467

Sequential X-Irradiation Induced Acquired Resistance to Oxaliplatin but Increased Sensitivity to Cisplatin in Two Human Teratoma Cell Lines In Vitro. S. EISENMANN, W. VOIGT, T. MÜLLER, W. DEMPKE (Halle/Saale, Germany) ................................................................. 4471

* Review: Brivanib, A Novel Dual VEGF-R2/bFGF-R Inhibitor. W.C.M. DEMPKE, R. ZIPPEL (Riesa, Germany) ........................................................................................................ 4477

Effect of β4 Integrin Knockdown by RNA Interference in Anaplastic Thyroid Carcinoma. T.W. NOH, Y.H. SOUNG, H.I. KIM, H.J. GIL, J.M. KIM, E.J. LEE, J. CHUNG (Seoul, Republic of Korea; Shreveport, LA, USA) ......... 4485

Altered Expression of Cell Cycle and Apoptotic Proteins in Human Liver Pathologies. A. MITSELOU, D. KARAPIPERIDES, I. NESSERIS, T. VOUGIOUKLAKIS, N. AGNANTIS (Ioannina; Thessaloniki, Greece) ........................................................................................................ 4493


The Antitumour Effect of γδ T-Cells is Enhanced by Valproic Acid-induced Up-regulation of NKG2D Ligands. T. SUZUKI, S. TERAO, B. ACHARYA, M. NAOE, S. YAMAMOTO, H. OKAMURA, A. GOTOH (Hyogo; Tokyo, Japan) ........................................................................................................ 4509

Invasion of Human Glioma Cells Is Regulated by Multiple Chloride Channels Including CIC-3. V.C.H. LUI, S.S.S. LUNG, J.K.S. PU, K.N. HUNG, G.K.K. LEUNG (Pokfulam, Hong Kong, P.R.C.) .......... 4515

ITF2357 Interferes with Apoptosis and Inflammatory Pathways in the HL-60 Model: A Gene Expression Study. S. GALIMBERTI, M. CANESTRARO, H. SAVLI, G.A. PALUMBO, D. TIBULLO, B. NAGY, S. PIAGGI, F. GUERRINI, N. CINE, M.R. METELLI, M. PETRINI (Pisa; Catania, Italy; Kocaeli, Turkey; Budapest, Hungary) ........................................................................................................ 4525

Genistein Increases Gene Expression by Demethylation of WNT5a Promoter in Colon Cancer Cell Line SW1116. Z. WANG, H. CHEN (Urbana, IL, USA) ........................................................................................................ 4537

Synergism from Combination of Cisplatin and a Trans-Platinum Compound in Ovarian Cancer Cell Lines. A. ALSHEHRI, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Sydney, NSW, Australia) ........................................................................................................ 4547


Contents continued on the preceding page